Discover undervalued stocks with Eulerpool.

Subscribe for $2

Personalis Stock PSNL

Price

0
Today +/-
-0
Today %
-0 %

Personalis stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Personalis stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Personalis stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Personalis stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Personalis's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Personalis Stock Price History

DatePersonalis Price
10/8/20250 undefined
10/7/20257.89 undefined
10/7/20257.66 undefined
10/6/20257.11 undefined
10/3/20257.34 undefined
10/3/20257.31 undefined
10/2/20256.78 undefined
10/1/20256.89 undefined
9/30/20256.54 undefined
9/28/20256.35 undefined
9/25/20256.04 undefined
9/24/20255.98 undefined
9/24/20256.00 undefined
9/23/20256.19 undefined
9/22/20256.23 undefined
9/19/20256.11 undefined
9/18/20255.82 undefined
9/17/20255.62 undefined
9/16/20255.94 undefined
9/15/20255.96 undefined
9/12/20255.87 undefined
9/11/20256.01 undefined
9/10/20255.39 undefined
9/9/20255.41 undefined
9/8/20255.32 undefined

Personalis Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Personalis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Personalis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Personalis’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Personalis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Personalis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Personalis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Personalis’s growth potential.

Personalis Revenue, EBIT and net profit per share

DatePersonalis RevenuePersonalis EBITPersonalis Net Income
2030e482.06 M undefined142.97 M undefined32.64 M undefined
2029e298.84 M undefined-4.8 M undefined-4.53 M undefined
2028e200.03 M undefined-44.02 M undefined-23.27 M undefined
2027e124.77 M undefined-81.35 M undefined-47 M undefined
2026e96.87 M undefined-90.62 M undefined-55.84 M undefined
2025e74.61 M undefined-92.96 M undefined-58.28 M undefined
202484.61 M undefined-68.27 M undefined-81.28 M undefined
202373.48 M undefined-96.29 M undefined-108.3 M undefined
202265.05 M undefined-115.53 M undefined-113.32 M undefined
202185.49 M undefined-65.35 M undefined-65.23 M undefined
202078.65 M undefined-42.15 M undefined-41.28 M undefined
201965.21 M undefined-22.42 M undefined-25.08 M undefined
201837.77 M undefined-13.77 M undefined-19.89 M undefined
20179.39 M undefined-22.16 M undefined-23.6 M undefined

Personalis Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201720182019202020212022202320242025e2026e2027e2028e2029e2030e
9376578856573847496124200298482
-311.1175.6820.008.97-23.5312.3115.07-11.9029.7329.1761.2949.0061.74
-22.2229.7333.8525.6436.4720.0024.6630.9535.1427.0820.9713.008.725.39
-211222031131826000000
-23-19-25-41-65-113-108-81-58-55-46-23-432
--17.3931.5864.0058.5473.85-4.42-25.00-28.40-5.17-16.36-50.00-82.61-900.00
28.528.518.0134.3743.8945.748.1859.25000000
- - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Personalis Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Personalis is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20172018201920202021202220232024
               
22.619.7128.3203.3287.1167.7114.18185.01
1.94.53.36.318.516.617.738.14
00000000
1.42.14.65.65.68.610.475.94
0.83.23.45.47.16.84.363.93
26.729.5139.6220.6318.3199.7146.74203.02
6.311.51622.173.588.475.2264.73
00000000
00000000
00000000
00000000
0.50.71.824.84.63.142.53
6.812.217.824.178.39378.3667.25
33.541.7157.4244.7396.6292.7225.1270.27
               
7689.400000.010.01
39.1247.3376.8557.6579.5598.36752.96
-95.6-115.5-140.6-181.9-247.1-360.4-468.71-549.99
0000-0.2-0.9-0.22-0.02
00000000
-16.6-17106.7194.9310.3218.2129.44202.96
46.67.38.39.212.914.926.4
2.63.16.210.815.316.121.4416.24
24.943.236.421.5529.236.82
17.55000000
00001.82.21.651.67
4957.949.940.631.333.247.2331.13
0.30.7001.70.41.230.1
00000000
0.90.10.69.353.241.147.1936.08
1.20.80.69.354.941.548.4236.19
50.258.750.549.986.274.795.6667.31
33.641.7157.2244.8396.5292.9225.1270.27
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Personalis provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Personalis's financial health and stability.

Assets

Personalis's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Personalis must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Personalis after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Personalis's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (k)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-23-19-25-41-65-113-108
13456811
0000000
2015-7-17-311013
281418334327
001,0000000
0000000
05-18-42-70-70-56
-5-7-8-3-11-49-10
-5-7-81-65-605213
00-73-61-4810224
0000000
160-503-16
0014512116624
160134121169111
---4.00----
0000000
11-2351338-16-32
-4.87-2.28-26.45-45.9-81.91-120.13-67.17
0000000

Personalis stock margins

The Personalis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Personalis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Personalis.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Personalis's sales revenue. A higher gross margin percentage indicates that the Personalis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Personalis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Personalis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Personalis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Personalis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Personalis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Personalis Margin History

Personalis Gross marginPersonalis Profit marginPersonalis EBIT marginPersonalis Profit margin
2030e31.7 %29.66 %6.77 %
2029e31.7 %-1.61 %-1.52 %
2028e31.7 %-22.01 %-11.63 %
2027e31.7 %-65.2 %-37.67 %
2026e31.7 %-93.55 %-57.65 %
2025e31.7 %-124.58 %-78.11 %
202431.7 %-80.68 %-96.06 %
202324.78 %-131.05 %-147.38 %
202220.52 %-177.6 %-174.2 %
202137.03 %-76.44 %-76.3 %
202025.57 %-53.59 %-52.49 %
201933.86 %-34.38 %-38.46 %
201831.27 %-36.46 %-52.66 %
2017-24.92 %-236 %-251.33 %

Personalis Stock Sales Revenue, EBIT, Earnings per Share

The Personalis earnings per share therefore indicates how much revenue Personalis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Personalis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Personalis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Personalis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Personalis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Personalis Revenue, EBIT and net profit per share

DatePersonalis Sales per SharePersonalis EBIT per sharePersonalis Earnings per Share
2030e8.14 undefined0 undefined0.55 undefined
2029e5.04 undefined0 undefined-0.08 undefined
2028e3.38 undefined0 undefined-0.39 undefined
2027e2.11 undefined0 undefined-0.79 undefined
2026e1.63 undefined0 undefined-0.94 undefined
2025e1.26 undefined0 undefined-0.98 undefined
20241.43 undefined-1.15 undefined-1.37 undefined
20231.53 undefined-2 undefined-2.25 undefined
20221.42 undefined-2.53 undefined-2.48 undefined
20211.95 undefined-1.49 undefined-1.49 undefined
20202.29 undefined-1.23 undefined-1.2 undefined
20193.62 undefined-1.24 undefined-1.39 undefined
20181.33 undefined-0.48 undefined-0.7 undefined
20170.33 undefined-0.78 undefined-0.83 undefined

Personalis business model

Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.com.

Personalis SWOT Analysis

Strengths

Personalis Inc, being a leading genomic data company, possesses several strengths that give it a competitive edge in the market. These strengths include:

  • Cutting-edge technology and expertise in genomics
  • Strong partnerships with top pharmaceutical and biotech companies
  • Wide range of genomic analysis services
  • Strong track record of delivering accurate and reliable results
  • Ability to handle large-scale genomic data and provide meaningful insights

Weaknesses

Despite its strengths, Personalis Inc also faces certain weaknesses that need to be addressed to maintain its competitive position:

  • Dependence on collaborations for research and development
  • Relatively high cost of its genomic analysis services compared to competitors
  • Limited brand awareness outside the genomics industry
  • Potential for data privacy and security concerns
  • Lack of diversification in service offerings

Opportunities

Personalis Inc has several opportunities that it can capitalize on to further grow and expand its business:

  • Increasing demand for genomic data in precision medicine
  • Growing interest in personalized healthcare and diagnostics
  • Emerging markets for genomic analysis services
  • Potential for strategic partnerships with healthcare providers
  • Expanding use of genomics in agriculture and veterinary sciences

Threats

Personalis Inc should also be aware of potential threats that could impact its business and take necessary precautions:

  • Intense competition from established genomics companies
  • Regulatory challenges and evolving industry standards
  • Economic downturns affecting healthcare spending
  • Rapid technological advancements making current offerings obsolete
  • Potential legal and ethical concerns surrounding genomic data usage
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Personalis Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Personalis historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Personalis shares outstanding

The number of shares was Personalis in 2024 — This indicates how many shares 59.251 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Personalis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Personalis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Personalis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Personalis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Personalis.

Personalis latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.25 -0.23  (7.48 %)2025 Q2
3/31/2025-0.25 -0.18  (28.6 %)2025 Q1
12/31/2024-0.29 -0.23  (20.88 %)2024 Q4
9/30/2024-0.36 -0.64  (-79.27 %)2024 Q3
6/30/2024-0.38 -0.24  (36.97 %)2024 Q2
3/31/2024-0.41 -0.26  (37.32 %)2024 Q1
12/31/2023-0.51 -0.54  (-5.88 %)2023 Q4
9/30/2023-0.54 -0.48  (10.56 %)2023 Q3
6/30/2023-0.54 -0.5  (7.72 %)2023 Q2
3/31/2023-0.59 -0.61  (-2.61 %)2023 Q1
1
2
3

Eulerpool ESG Scorecard© for the Personalis stock

Eulerpool World ESG Rating (EESG©)

45/ 100

🌱 Environment

48

👫 Social

49

🏛️ Governance

37

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Personalis shareholders

%
Name
Stocks
Change
Date
23.70415 % Merck & Co Inc14,044,94306/30/2025
21.46597 % Tempus AI Inc12,718,8003,500,0008/16/2024
13.77316 % Lightspeed Venture Partners8,160,73406/30/2025
11.99629 % ARK Investment Management LLC7,107,923-80,2746/30/2025
6.40677 % BlackRock Institutional Trust Company, N.A.3,796,0752,096,5756/30/2025
5.29453 % The Vanguard Group, Inc.3,137,0611,846,4706/30/2025
4.70093 % AIGH Capital Management, LLC.2,785,350-194,5716/30/2025
2.96957 % abrdn Inc.1,759,49754,7136/30/2025
2.82915 % Blue Water Life Science Advisors, LP.1,676,300500,9006/30/2025
2.30477 % Geode Capital Management, L.L.C.1,365,598851,4226/30/2025
1
2
3
4
5
...
10

Personalis Executives and Management Board

Mr. Christopher Hall

(55)
Personalis President, Chief Executive Officer, Director (since 2022)
Compensation 1.73 M

Mr. Aaron Tachibana

(63)
Personalis Chief Financial Officer, Chief Operating Officer, Senior Vice President
Compensation 1.67 M

Dr. Richard Chen

(53)
Personalis Executive Vice President - Research and Development, Chief Medical Officer
Compensation 1.28 M

Mr. Stephen Moore

(52)
Personalis Senior Vice President, Chief Legal Officer, and Corporate Secretary
Compensation 674,279

Ms. Karin Eastham

(74)
Personalis Independent Chairman of the Board
Compensation 173,051
1
2

Most common questions regarding Personalis

What values and corporate philosophy does Personalis represent?

Personalis Inc represents a strong commitment to leveraging genomics to advance the field of precision medicine. The company focuses on providing comprehensive, accurate, and reliable genomic data to empower healthcare professionals and researchers. Personalis Inc values innovation and excellence in developing cutting-edge technologies to deliver personalized insights into an individual's genetic makeup. With an emphasis on collaboration and integrity, Personalis Inc aims to drive breakthroughs in disease research, drug development, and patient care. By harnessing the power of genomics, Personalis Inc is dedicated to improving health outcomes and transforming the future of precision medicine.

In which countries and regions is Personalis primarily present?

Personalis Inc is primarily present in the United States and operates globally.

What significant milestones has the company Personalis achieved?

Personalis Inc has achieved several significant milestones throughout its journey. One noteworthy achievement is the successful completion of its initial public offering (IPO) in June 2019, which marked a pivotal moment for the company. Additionally, Personalis Inc has made remarkable strides in the field of advanced genomics, providing comprehensive and accurate genomic sequencing and interpretation solutions. The company's commitment to innovation has led to various collaborations with renowned pharmaceutical and biotechnology companies, further strengthening its market position and expanding its reach. Through its consistent dedication, Personalis Inc has established itself as a leading player in the genomics industry.

What is the history and background of the company Personalis?

Personalis Inc. is a renowned genomic sequencing and data analysis company based in California. Founded in 2010, Personalis specializes in advanced technologies that enable the study of genomics at an unprecedented scale. The company combines extensive reference data with state-of-the-art analytics to provide accurate and comprehensive genomic information. Personalis has built strong capabilities in cancer genomics, aiding in the development of personalized cancer therapies. With its proprietary biotechnology platforms, Personalis offers highly accurate sequencing capabilities as well as innovative systems for analyzing genomic data. Continuously expanding its expertise and collaborations, Personalis Inc. remains at the forefront of genomic research and precision medicine.

Who are the main competitors of Personalis in the market?

The main competitors of Personalis Inc in the market include companies like Illumina, Inc., Foundation Medicine, Inc., and Exact Sciences Corporation.

In which industries is Personalis primarily active?

Personalis Inc is primarily active in the biotechnology industry.

What is the business model of Personalis?

The business model of Personalis Inc is focused on genomic data and precision medicine. The company offers advanced genomic sequencing and analysis services to researchers, pharmaceutical companies, and healthcare providers. Personalis Inc leverages its expertise in genomics to analyze and interpret genetic information, helping customers gain insights into complex diseases and develop targeted therapies. With a comprehensive suite of proprietary technologies and a vast genomic database, Personalis Inc aims to revolutionize healthcare by delivering personalized solutions for better patient outcomes.

What is the P/E ratio of Personalis 2025?

The P/E ratio cannot be calculated for Personalis at the moment.

What is the P/S ratio of Personalis 2025?

The P/S cannot be calculated for Personalis currently.

What is the Quality Investing of Personalis?

The Quality Investing for Personalis is 1/10.

What is the revenue of Personalis 2025?

The expected Personalis revenue is 74.61 M USD.

How high is the profit of Personalis 2025?

The expected Personalis profit is -58.28 M USD.

What is the business model of Personalis

Personalis Inc. is a company from the USA specializing in the development of personalized diagnostic and treatment solutions. The company operates in different sectors, each of which contributes uniquely to strengthening the company's life cycle. The first sector of Personalis is cancer genomics. The company has developed a platform that allows for the analysis of the genomics of cancer cells. The process involves sequencing DNA and RNA to obtain accurate information about the tumor type and its variations. With this information, Personalis develops strategies for the treatment of cancer patients and provides personalized treatment plans to its customers. Another important aspect of Personalis is genomics in immunology. Personalis utilizes its expertise to modulate the immune system of patients. The company has developed a technology that captures information about genetic variations in the immune system and uses this information to create personalized immunotherapies. This approach opens new avenues for developing treatment solutions for autoimmune diseases and other immune disorders. Personalis also has a services department that offers personalized diagnostic and treatment solutions to clinical and pharmaceutical customers. The company provides a wide range of services based on genomics, immunology, and other areas of personalized medicine. Personalis also serves the research sector through its services, equipping research laboratories in the biotechnology industry with the latest technologies to accelerate the progress of personalized medicine. The products offered by Personalis include the Cancer Genome Atlas (TCGA), a comprehensive dataset of DNA sequencing data provided to research laboratories to better understand cancer genomics and the mechanisms underlying cancer development. Personalis also offers the IMPACT test, a diagnostic platform that allows for the identification of genetic anomalies in cancer cells through sequencing. Personalis' business strategy focuses on the development of personalized diagnostic and treatment solutions, taking future advancements in medicine and biotechnology into account. Personalis aims to provide patients with the opportunity to receive the best possible treatment for their illness by leveraging the genetic information of their disease. In summary, Personalis Inc. offers innovative solutions for diagnostics and treatment through personalized medicine. With its expertise in genomics and immunology, the company covers various business fields. Personalis relies on the use of cutting-edge technologies to offer personalized solutions tailored to the specific needs of its customers. The company clearly positions itself as a leader in personalized medicine.

What is the Personalis dividend?

Personalis pays a dividend of 0 USD distributed over payouts per year.

How often does Personalis pay dividends?

The dividend cannot currently be calculated for Personalis or the company does not pay out a dividend.

What is the Personalis ISIN?

The ISIN of Personalis is US71535D1063.

What is the Personalis WKN?

The WKN of Personalis is A2PLTK.

What is the Personalis ticker?

The ticker of Personalis is PSNL.

How much dividend does Personalis pay?

Over the past 12 months, Personalis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Personalis is expected to pay a dividend of 0 USD.

What is the dividend yield of Personalis?

The current dividend yield of Personalis is .

When does Personalis pay dividends?

Personalis pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Personalis?

Personalis paid dividends every year for the past 0 years.

What is the dividend of Personalis?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Personalis located?

Personalis is assigned to the 'Health' sector.

Wann musste ich die Aktien von Personalis kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Personalis from 10/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2025.

When did Personalis pay the last dividend?

The last dividend was paid out on 10/8/2025.

What was the dividend of Personalis in the year 2024?

In the year 2024, Personalis distributed 0 USD as dividends.

In which currency does Personalis pay out the dividend?

The dividends of Personalis are distributed in USD.

All fundamentals about Personalis

Our stock analysis for Personalis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Personalis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.